// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

How insignificant are genetic variants of unknown significance in Primary Ciliary Dyskinesia?

Reena Bhatt - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Primary ciliary dyskinesia

Nitric oxide

A combination of biomarkers for fibrinolysis and basement membrane destruction predicts mortality in the ECLIPSE COPD cohort

Jannie Sand - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Desmosine is a predictor of long-term cardiovascular mortality in bronchiectasis

Jeffrey T.-J. Huang - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The long-term clinical and economic impact of COPD exacerbations: an observational study (SHERLOCK

John Haughney - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

European expert consensus on assessment and management of hospitalised exacerbations of COPD (CICERO ERS CRC

Sanjay Ramakrishnan - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Effect of maintenance oral corticosteroids on risk factors for frequent exacerbations in a severe adult asthma population

Jieqiong Yang - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Collating data from major European population studies – The CADSET (Chronic airway disease early stratification clinical research collaboration

James Allinson - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Comparison of spirometric markers of severity and reversibility in patients with asthma and/or COPD in NOVELTY

Rod Hughes - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

N/A

How different operators performing sputum eosinophil differential cell counts may affect clinical decisions for severe asthma patients

Gaël Tavernier - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Correlation between Blood Eosinophilia and Fractional Exhaled Nitric Oxide in the diagnosis of Asthma within Primary Care

Sudip Ghosh - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Nitric oxide

Cognitive decline following an acute exacerbation of COPD (AECOPD

Grace France - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Research priorities in alpha-1 antitrypsin deficiency (AATD for healthcare professionals

Miriam Barrecheguren Fernandez - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Alpha-1 antitrypsin (A1AT) deficiency

Alpha 1-Antitrypsin

Prevalence of alpha-1 antitrypsin deficiency (AATD in Greater Glasgow and Clyde (GG&C and current practises

Fiona Catterall - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Alpha-1 antitrypsin (A1AT) deficiency

Alpha 1-Antitrypsin

Late Breaking Abstract - Reimbursement for asthma care is a universal barrier to achieving asthma symptom control: the SABINA III study

Eric D. Bateman - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Characterising symptom ‘trajectotypes’ in patients with COPD

Andreas Halner - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Effectiveness of community-based interventions following multi disciplinary team discussion in COPD patients

Cecillia Rafique - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Anxiety

N/A

Key findings and quality improvement recommendatons from the national asthma and COPD audit programme (NACAP primary care audit April 2017- September 2018

Eloya Imoedemhe - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

N/A

Anti-DP effects on airway bacterial load in a phase 2a trial

Sarah Diver - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Estimating Chronic Respiratory Disease (Asthma and COPD burden in adults in Asian LMICs: a pilot study for 4CCORD [4 Country ChrOnic Respiratory Disease study]

Dhiraj Agarwal - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

N/A

Determinants of arterial stiffness in Alpha-1 Antitrypsin Deficiency

Abubacarr Gassama - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Alpha-1 antitrypsin (A1AT) deficiency

Alpha 1-Antitrypsin

Copyright © 2026. QuantiNova All rights reserved